retatrutide phase 3 results just delivered the first top-line for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 retatrutide weight loss clinical data

Retatrutide is an investigational triple hormone receptor agonist being developed by Eli Lilly

164 PrikhodkoVABezborodkinaNNOkovityiSV

EXSCEL found a 9% reduction in the relative risk (RR) of three-point MACE

Although there have been no specific trials to show cardiorenal benefit for GLP-1RA or SGLT2i when used as first-line therapy or as monotherapy or in newly diagnosed T2D, the benefit seen in the CV outcome trials has not been found to vary with the duration of diabetes, suggesting that similar benefits might be seen early in the course of disease.4 The benefits are also not dependent on the presence of metformin

Supplements: Enhance your horse's overall well-being with our horse-friendly supplements designed to support their health and performance

IGF influences the cellular differentiation of ovary granulosa cells